The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant
© 2021. The Author(s)..
PURPOSE: To evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes.
METHODS: We included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk.
RESULTS: For BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06-1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07-1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC < age 40 years, the cumulative PRS313 5th and 95th percentile 10-year CBC risks were 22% and 32% for BRCA1 and 13% and 23% for BRCA2 heterozygotes, respectively.
CONCLUSION: The PRS313 can be used to refine individual CBC risks for BRCA1/2 heterozygotes of European ancestry, however the PRS313 needs to be considered in the context of a multifactorial risk model to evaluate whether it might influence clinical decision-making.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Genetics in medicine : official journal of the American College of Medical Genetics - 23(2021), 9 vom: 01. Sept., Seite 1726-1737 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
BRCA1 Protein |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41436-021-01198-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326609768 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326609768 | ||
| 003 | DE-627 | ||
| 005 | 20240210232348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41436-021-01198-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM326609768 | ||
| 035 | |a (NLM)34113011 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lakeman, Inge M M |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a PURPOSE: To evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes | ||
| 520 | |a METHODS: We included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk | ||
| 520 | |a RESULTS: For BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06-1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07-1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC < age 40 years, the cumulative PRS313 5th and 95th percentile 10-year CBC risks were 22% and 32% for BRCA1 and 13% and 23% for BRCA2 heterozygotes, respectively | ||
| 520 | |a CONCLUSION: The PRS313 can be used to refine individual CBC risks for BRCA1/2 heterozygotes of European ancestry, however the PRS313 needs to be considered in the context of a multifactorial risk model to evaluate whether it might influence clinical decision-making | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a BRCA1 protein, human |2 NLM | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a BRCA2 protein, human |2 NLM | |
| 700 | 1 | |a van den Broek, Alexandra J |e verfasserin |4 aut | |
| 700 | 1 | |a Vos, Juliën A M |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Daniel R |e verfasserin |4 aut | |
| 700 | 1 | |a Adlard, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Andrulis, Irene L |e verfasserin |4 aut | |
| 700 | 1 | |a Arason, Adalgeir |e verfasserin |4 aut | |
| 700 | 1 | |a Arnold, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Arun, Banu K |e verfasserin |4 aut | |
| 700 | 1 | |a Balmaña, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Barrowdale, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Benitez, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Borg, Ake |e verfasserin |4 aut | |
| 700 | 1 | |a Caldés, Trinidad |e verfasserin |4 aut | |
| 700 | 1 | |a Caligo, Maria A |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Wendy K |e verfasserin |4 aut | |
| 700 | 1 | |a Claes, Kathleen B M |e verfasserin |4 aut | |
| 700 | 0 | |a GEMO Study Collaborators |e verfasserin |4 aut | |
| 700 | 0 | |a EMBRACE Collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Collée, J Margriet |e verfasserin |4 aut | |
| 700 | 1 | |a Couch, Fergus J |e verfasserin |4 aut | |
| 700 | 1 | |a Daly, Mary B |e verfasserin |4 aut | |
| 700 | 1 | |a Dennis, Joe |e verfasserin |4 aut | |
| 700 | 1 | |a Dhawan, Mallika |e verfasserin |4 aut | |
| 700 | 1 | |a Domchek, Susan M |e verfasserin |4 aut | |
| 700 | 1 | |a Eeles, Ros |e verfasserin |4 aut | |
| 700 | 1 | |a Engel, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, D Gareth |e verfasserin |4 aut | |
| 700 | 1 | |a Feliubadaló, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Foretova, Lenka |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Eitan |e verfasserin |4 aut | |
| 700 | 1 | |a Frost, Debra |e verfasserin |4 aut | |
| 700 | 1 | |a Ganz, Patricia A |e verfasserin |4 aut | |
| 700 | 1 | |a Garber, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Gayther, Simon A |e verfasserin |4 aut | |
| 700 | 1 | |a Gerdes, Anne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Godwin, Andrew K |e verfasserin |4 aut | |
| 700 | 1 | |a Goldgar, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Hahnen, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Hake, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Hamann, Ute |e verfasserin |4 aut | |
| 700 | 1 | |a Hogervorst, Frans B L |e verfasserin |4 aut | |
| 700 | 1 | |a Hooning, Maartje J |e verfasserin |4 aut | |
| 700 | 1 | |a Hopper, John L |e verfasserin |4 aut | |
| 700 | 1 | |a Hulick, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Imyanitov, Evgeny N |e verfasserin |4 aut | |
| 700 | 0 | |a OCGN Investigators |e verfasserin |4 aut | |
| 700 | 0 | |a HEBON Investigators |e verfasserin |4 aut | |
| 700 | 0 | |a KconFab Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Isaacs, Claudine |e verfasserin |4 aut | |
| 700 | 1 | |a Izatt, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Jakubowska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a James, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Janavicius, Ramunas |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Uffe Birk |e verfasserin |4 aut | |
| 700 | 1 | |a Jiao, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a John, Esther M |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Vijai |e verfasserin |4 aut | |
| 700 | 1 | |a Karlan, Beth Y |e verfasserin |4 aut | |
| 700 | 1 | |a Kets, Carolien M |e verfasserin |4 aut | |
| 700 | 1 | |a Konstantopoulou, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Kwong, Ava |e verfasserin |4 aut | |
| 700 | 1 | |a Legrand, Clémentine |e verfasserin |4 aut | |
| 700 | 1 | |a Leslie, Goska |e verfasserin |4 aut | |
| 700 | 1 | |a Lesueur, Fabienne |e verfasserin |4 aut | |
| 700 | 1 | |a Loud, Jennifer T |e verfasserin |4 aut | |
| 700 | 1 | |a Lubiński, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Manoukian, Siranoush |e verfasserin |4 aut | |
| 700 | 1 | |a McGuffog, Lesley |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Austin |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Denise Molina |e verfasserin |4 aut | |
| 700 | 1 | |a Montagna, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Mouret-Fourme, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Nathanson, Katherine L |e verfasserin |4 aut | |
| 700 | 1 | |a Neuhausen, Susan L |e verfasserin |4 aut | |
| 700 | 1 | |a Nevanlinna, Heli |e verfasserin |4 aut | |
| 700 | 1 | |a Yie, Joanne Ngeow Yuen |e verfasserin |4 aut | |
| 700 | 1 | |a Olah, Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Olopade, Olufunmilayo I |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sue K |e verfasserin |4 aut | |
| 700 | 1 | |a Parsons, Michael T |e verfasserin |4 aut | |
| 700 | 1 | |a Peterlongo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Piedmonte, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Radice, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Rantala, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Rennert, Gad |e verfasserin |4 aut | |
| 700 | 1 | |a Risch, Harvey A |e verfasserin |4 aut | |
| 700 | 1 | |a Schmutzler, Rita K |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Simard, Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Christian F |e verfasserin |4 aut | |
| 700 | 1 | |a Stadler, Zsofia |e verfasserin |4 aut | |
| 700 | 1 | |a Stoppa-Lyonnet, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Sutter, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Yen Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira, Manuel R |e verfasserin |4 aut | |
| 700 | 1 | |a Teo, Soo Hwang |e verfasserin |4 aut | |
| 700 | 1 | |a Teulé, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Thomassen, Mads |e verfasserin |4 aut | |
| 700 | 1 | |a Thull, Darcy L |e verfasserin |4 aut | |
| 700 | 0 | |a et al |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Genetics in medicine : official journal of the American College of Medical Genetics |d 1997 |g 23(2021), 9 vom: 01. Sept., Seite 1726-1737 |w (DE-627)NLM097536970 |x 1530-0366 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:9 |g day:01 |g month:09 |g pages:1726-1737 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41436-021-01198-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 9 |b 01 |c 09 |h 1726-1737 | ||